Aura Biosciences (NASDAQ:AURA) PT Raised to $22.00 at HC Wainwright

Aura Biosciences (NASDAQ:AURA) had its price objective hoisted by research analysts at HC Wainwright from $21.00 to $22.00 in a report released on Friday, MarketBeat.com reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 87.39% from the company’s current price.

Several other research firms have also weighed in on AURA. Lifesci Capital upgraded shares of Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 9th. Evercore ISI upgraded shares of Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 16th. Finally, JMP Securities increased their price objective on shares of Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a research note on Friday, September 13th. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $23.00.

Aura Biosciences Stock Performance

Shares of AURA stock opened at $11.74 on Friday. Aura Biosciences has a one year low of $5.99 and a one year high of $12.38. The company’s 50-day simple moving average is $8.66 and its 200-day simple moving average is $8.06. The stock has a market capitalization of $581.63 million, a price-to-earnings ratio of -6.31 and a beta of 0.37.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.04. As a group, research analysts forecast that Aura Biosciences will post -1.7 EPS for the current year.

Insider Buying and Selling at Aura Biosciences

In other Aura Biosciences news, insider Los Pinos Elisabet De sold 24,992 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $12.04, for a total value of $300,903.68. Following the sale, the insider now owns 329,847 shares in the company, valued at approximately $3,971,357.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Aura Biosciences news, insider Los Pinos Elisabet De sold 24,992 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $12.04, for a total value of $300,903.68. Following the sale, the insider now owns 329,847 shares in the company, valued at approximately $3,971,357.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CTO Mark Plavsic sold 7,383 shares of the firm’s stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $9.85, for a total transaction of $72,722.55. Following the completion of the sale, the chief technology officer now owns 121,132 shares in the company, valued at $1,193,150.20. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 5.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Long Focus Capital Management LLC boosted its holdings in shares of Aura Biosciences by 113.4% in the second quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock valued at $7,992,000 after acquiring an additional 561,766 shares in the last quarter. Regency Capital Management Inc. DE boosted its holdings in shares of Aura Biosciences by 11.4% in the first quarter. Regency Capital Management Inc. DE now owns 785,136 shares of the company’s stock valued at $6,163,000 after acquiring an additional 80,162 shares in the last quarter. Levin Capital Strategies L.P. boosted its holdings in shares of Aura Biosciences by 194.5% in the second quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company’s stock valued at $2,476,000 after acquiring an additional 216,266 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Aura Biosciences by 20.0% during the second quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock worth $1,892,000 after buying an additional 41,711 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Aura Biosciences by 51.4% during the second quarter. Bank of New York Mellon Corp now owns 143,027 shares of the company’s stock worth $1,081,000 after buying an additional 48,549 shares in the last quarter. 96.75% of the stock is currently owned by institutional investors.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.